Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A phase 3 trial testing Atebimetinib in pancreatic ductal adenocarcinoma, now recruiting.
Overview
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07562152, led by Immuneering, and recruiting when checked on 2026-09-11. Official title: A Phase 3 Randomised, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301). Planned enrolment is 510 participants (estimated). The study started in 2026-06-05 and primary completion is expected in 2028-06. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialStudy of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialPhase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.